<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411957</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-NAT 073</org_study_id>
    <nct_id>NCT00411957</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of 2 Doses of ATV/r OD + 2 NRTIs in Thai HIV-1 Infected Patients</brief_title>
  <official_title>The Pharmacokinetics of Atazanavir / Ritonavir 200/100 OD Versus 300/100 mg OD in Combination With 2 NRTIs in HIV Pre-treated Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The HIV Netherlands Australia Thailand Research Collaboration</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several studies from HIV-NAT have demonstrated high nevirapine, indinavir, saquinavir and
      lopinavir/r levels when compared to Caucasian patients. Until now, the pharmacokinetics of
      atazanavir have not been explored in a Thai population. We postulate that ATV levels, as with
      other PIs, are higher in Thai people. Therefore, the level of ATV in ATV/RTV 300/100 OD may
      be higher than the acceptable range and could be associated with ATV related toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We are interested in once daily ATV/RTV 200/100 mg OD because of the convenience, reduction
      in ATV doses which may improve adherence while reducing toxicity and cost. There are limited
      prospective studies evaluating pharmacokinetic and long term efficacy and safety of
      atazanavir/ritonavir once daily dose in combination of NRTIs in HIV-1 pretreated patients. We
      believe that the PK parameters of ATV/RTV given at 200/100mg daily in Thai patients will be
      equivalent to the ATV/RTV 300/100mg once daily dosing in Caucasian patients when combined
      with 2NRTIs, and that the once daily regimen will have better safety, tolerability profile,
      and cost saving while maintaining good CD4 and VL outcome. If, the pharmacokinetic profile of
      ATV/RTV 200/100 mg OD + 2NRTIs is in acceptable range or comparable with standard dose of
      ATV/RTV 300/100 mg OD, long term efficacy will be explored later.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the pharmacokinetics of atazanavir/ritonavir (ATV/RTV) 200/100 mg once daily in a sample of 22 patients experiencing virological success</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetic and pharmacodynamic between these patients and data from Thai cohort treated with ATV/RTV 300/100 mg OD</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>short term safety, tolerability and efficacy data in these PK participating patients</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ATV/r 300/100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ATV/r 200/100 mg OD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>ATV/r 300/100mg OD vs ATV/r 200/100 mg OD</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Adults HIV patients currently using ATV/RTV 300/100 mg OD plus 2 NRTIs

          -  HIV RNA &lt; 50 copies/ml

        Exclusion Criteria:

          -  Inability to understand the nature and extent of the study and the procedures
             required.

          -  ALT/ AST more than 5x upper limit

          -  Relevant history or current condition, illness that might interfere with drug
             absorption, distribution, metabolism or excretion.

          -  Use of concomitant medication that may interfere with the pharmacokinetics of
             atazanavir, and ritonavir

          -  History of sensitivity/idiosyncrasy to the drug or chemically related compounds which
             may be employed in the study.

          -  Active drug abuse or heavy alcoholic drinking

          -  History of sensitivity/idiosyncrasy to the drug or chemically related compounds which
             may be employed in the study.

          -  Active drug abuse or heavy alcoholic drinking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiat Ruxrungtham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HIV-NAT Thai Red Cross AIDS Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HIV-NAT, Thai Red Cross AIDS Research Center</name>
      <address>
        <city>Bangkok</city>
        <zip>10300</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.hivnat.org</url>
    <description>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</description>
  </link>
  <results_reference>
    <citation>Avihingsanon A, van der Lugt J, Kerr SJ, Gorowara M, Chanmano S, Ohata P, Lange J, Cooper DA, Phanuphak P, Burger DM, Ruxrungtham K. A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults. Clin Pharmacol Ther. 2009 Apr;85(4):402-8. doi: 10.1038/clpt.2008.244. Epub 2008 Dec 31.</citation>
    <PMID>19118378</PMID>
  </results_reference>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2006</study_first_submitted>
  <study_first_submitted_qc>December 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2006</study_first_posted>
  <last_update_submitted>June 4, 2010</last_update_submitted>
  <last_update_submitted_qc>June 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Kiat Ruxrungtham</name_title>
    <organization>HIV-NAT</organization>
  </responsible_party>
  <keyword>atazanavir/ritonavir</keyword>
  <keyword>pharmacokinetic of ATV/r200/100 OD+2NRTIs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

